Brain, Vol. 126, No. 2, 413-423,
February 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg028
The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients
1 Neuromuscular Center, Institute for Exercise and Environmental Medicine of Presbyterian Hospital, Dallas 2 The University of Texas Southwestern Medical Center and the VA Medical Center, Dallas, TX, 3 Department of Molecular and Medical Genetics, Oregon Health Science University, Portland, OR, 4 Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA and 5 Copenhagen Muscle Research Center and Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Correspondence to: Ronald G. Haller, MD, Neuromuscular Center, IEEM, 7232 Greenville Avenue, Dallas, TX 75231, USA Email: rhaller2{at}earthlink.net
Impaired skeletal muscle oxidative phosphorylation in patients with severe mitochondrial respiratory chain defects results in disabling exercise intolerance that is associated with a markedly blunted capacity of muscle to increase oxygen utilization in relation to circulatory and ventilatory responses that increase oxygen delivery to muscle during exercise. The range of oxidative limitation and the relationship between the severity of oxidative defects and physiological responses to exercise among a broader spectrum of mitochondrial respiratory chain defects has not been defined. We evaluated oxidative capacity and circulatory and ventilatory responses to maximal cycle exercise in 40 patients with biochemically and/or molecularly defined mitochondrial myopathy (MM) associated with varying levels of exercise tolerance, and compared responses with those in healthy sedentary individuals. In the MM patients, mean peak work capacity (0.88 ± 0.6 W/kg) and oxygen uptake (VO2, 16 ± 8 ml/kg/min) were significantly lower (P < 0.01) than in controls (mean work capacity = 2.2 ± 0.7 W/kg; VO2 = 32 ± 7 ml/kg/min), but the patient range was broad (0.17–3.2 W/kg; 6–47 ml/kg/min). Oxidative capacity in patients was limited by the ability of muscle to extract available oxygen from blood [mean peak systemic arteriovenous O2 difference (a–vO2); patients = 7.7 ± 3.5, range 2.7–17.6 ml/dl, controls = 15.2 ± 2.1 ml/dl], as indicated by a linear correlation between peak VO2 and peak systemic a–vO2 difference (r2 = 0.69). In the patients, the increase in cardiac output relative to VO2 (mean 
Q/VO2 = 15.0 ± 13.6; range 3.3–73) and ventilation (mean peak VE/VO2 = 65 ± 24; range 21–104) were exaggerated compared with controls (mean Q/VO2 = 5.1 ± 0.7; VE/VO2 = 41.2 ± 7.4, P < 0.01). There was a negative exponential relationship between Q/VO2 and peak systemic a–vO2 difference (r2 = 0.92) and between peak VE/VO2 and systemic a–vO2 difference (r2 = 0.53). In patients with heteroplasmic mtDNA mutations, we found an inverse relationship between the proportion of skeletal muscle mutant mtDNA and peak extraction of available oxygen during exercise (r2 = 0.70). We conclude that the degree of exercise intolerance in MM correlates directly with the severity of impaired muscle oxidative phosphorylation as indicated by the peak capacity for muscle oxygen extraction. Exaggerated circulatory and ventilatory responses to exercise are direct consequences of the level of impaired muscle oxidative phosphorylation and increase exponentially in relation to an increasing severity of oxidative impairment. In patients with mtDNA mutations, muscle mutation load governs mitochondrial capacity for oxidative phosphorylation and determines exercise capacity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Aboussouan Mechanisms of exercise limitation and pulmonary rehabilitation for patients with neuromuscular disease Chronic Respiratory Disease, November 1, 2009; 6(4): 231 - 249. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Frederiksen, T. D. Jeppesen, J. Vissing, M. Schwartz, K. O. Kyvik, O. Schmitz, P. L. Poulsen, and P. H. Andersen High Prevalence of Impaired Glucose Homeostasis and Myopathy in Asymptomatic and Oligosymptomatic 3243A>G Mitochondrial DNA Mutation-Positive Subjects J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2872 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Jeppesen, M. C. Orngreen, G. van Hall, R. G. Haller, and J. Vissing Fat Metabolism During Exercise in Patients With Mitochondrial Disease Arch Neurol, March 1, 2009; 66(3): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Arena, J. Myers, and M. Guazzi The Clinical Significance of Aerobic Exercise Testing and Prescription: From Apparently Healthy to Confirmed Cardiovascular Disease American Journal of Lifestyle Medicine, November 1, 2008; 2(6): 519 - 536. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. Murphy, E. L. Blakely, A. M. Schaefer, L. He, P. Wyrick, R. G. Haller, R. W. Taylor, D. M. Turnbull, and T. Taivassalo Resistance training in patients with single, large-scale deletions of mitochondrial DNA Brain, November 1, 2008; 131(11): 2832 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Levine : what do we know, and what do we still need to know? J. Physiol., January 1, 2008; 586(1): 25 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Adhihetty, T. Taivassalo, R. G. Haller, D. R. Walkinshaw, and D. A. Hood The effect of training on the expression of mitochondrial biogenesis- and apoptosis-related proteins in skeletal muscle of patients with mtDNA defects Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E672 - E680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Palange, S. A. Ward, K-H. Carlsen, R. Casaburi, C. G. Gallagher, R. Gosselink, D. E. O'Donnell, L. Puente-Maestu, A. M. Schols, S. Singh, et al. Recommendations on the use of exercise testing in clinical practice Eur. Respir. J., January 1, 2007; 29(1): 185 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Jeppesen, M. Schwartz, A. L. Frederiksen, F. Wibrand, D. B. Olsen, and J. Vissing Muscle Phenotype and Mutation Load in 51 Persons With the 3243A>G Mitochondrial DNA Mutation Arch Neurol, December 1, 2006; 63(12): 1701 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Taivassalo, J. L. Gardner, R. W. Taylor, A. M. Schaefer, J. Newman, M. J. Barron, R. G. Haller, and D. M. Turnbull Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions Brain, December 1, 2006; 129(12): 3391 - 3401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Durham, D. T. Brown, D. M. Turnbull, and P. F. Chinnery Progressive depletion of mtDNA in mitochondrial myopathy Neurology, August 8, 2006; 67(3): 502 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vissing, B. Quistorff, and R. G. Haller Effect of Fuels on Exercise Capacity in Muscle Phosphoglycerate Mutase Deficiency Arch Neurol, September 1, 2005; 62(9): 1440 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Horvath, H Lochmuller, M Hoeltzenbein, J Muller-Hocker, B G Schoser, D Pongratz, and M Jaksch Spontaneous recovery of a childhood onset mitochondrial myopathy caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene J. Med. Genet., June 1, 2004; 41(6): e75 - e75. [Full Text] [PDF]
|
|
|
|
|
|
G. E. Duncan, L. A. Perkins, D. W. Theriaque, R. E. Neiberger, and P. W. Stacpoole Dichloroacetate Therapy Attenuates the Blood Lactate Response to Submaximal Exercise in Patients with Defects in Mitochondrial Energy Metabolism J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1733 - 1738. [Abstract] [Full Text] [PDF]
|
|